Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

Trial Details

NCT ID

NCT07558733

Phase

PHASE1 / PHASE2

Sponsor

Faeth Therapeutics

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

Serabelisib
Sapanisertib
Fulvestrant

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368
Springfield, Oregon, United States|44.04624,-123.02203
Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

Histologically confirmed diagnosis of HR+/HER2- breast cancer.
Documented evidence of advanced or recurrent disease that is not amenable to surgery/radiation for curative intent.
Participant has received at least one prior systemic therapy.
At least 1 measurable or evaluable target lesion according to RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →